A Phase 3 interventional study of CSL511 Fibrinogen concentrate (human) and Cryoprecipitate in Acquired Fibrinogen Deficiency, sponsored by CSL Behring. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CSL511 or cryoprecipitate.
32 studies on the registry are indexed under Afibrinogenemia; 5 are open to participants now.
This study's planned enrollment of 90 is above the median of 40 across 19 interventional studies indexed under Afibrinogenemia.
Browse Afibrinogenemia studies →CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
First submitted after CSL Behring became part of CSL Limited.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: CSL511 Fibrinogen concentrate (human)
Biological: Cryoprecipitate
CSL511 will be prepared in sterile water for injection and administered as an intravenous (IV) infusion.
Cryoprecipitate will be administered via IV infusion.
Percentage of participants with overall hemostatic success
Overall hemostatic success will be assessed by an independent data monitoring and efficacy adjudication committee (IDMEAC). The IDMEAC will assess the overall efficacy based on a composite of intraoperative and postoperative hemostasis using a 4-point scale, where ratings correspond to excellent or good (hemostatic success) or moderate or none (hemostatic failure).
Time frame: During surgery to 24 hours after surgery
Number of participants with treatment-emergent (TE): adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs)
The TE AESIs include thromboembolic events, viral transmission/seroconversion, and anaphylaxis and severe hypersensitivity/severe allergic reactions.
Time frame: Up to 30 days after IV infusion
Number of participants with intraoperative hemostatic efficacy
Intraoperative hemostatic efficacy will be assessed by the surgeon and anesthesiologist using an objective 4-point hemostatic efficacy scale, where ratings correspond to excellent or good (hemostatic success) or moderate or none (hemostatic failure).
Time frame: During surgery
Number of participants with postoperative hemostatic efficacy
Postoperative hemostatic efficacy will be assessed by a hematologist using an objective 4-point hemostatic efficacy scale, where ratings correspond to excellent or good (hemostatic success) or moderate or none (hemostatic failure).
Time frame: Up to 24 hours after surgery
Plasma fibrinogen concentration
Time frame: During surgery, at the end of surgery and up to 24 hours after start of surgery
Mean total dose of fibrinogen administered
Time frame: During surgery, at the end of surgery and up to 24 hours after start of surgery
Number of doses of fibrinogen administered
Time frame: During surgery, at the end of surgery and up to 72 hours after start of surgery
Duration of surgery
Time frame: During surgery
Intraoperative blood loss
Time frame: During surgery
Intraoperative requirements for blood products
Blood products include fresh frozen plasma, red blood cells, and platelets.
Time frame: During surgery
Postoperative blood loss
Time frame: Up to 48 hours after start of surgery
Postoperative requirements for blood products
Blood products include fresh frozen plasma, red blood cells, and platelets.
Time frame: Up to 9 days after surgery
Number of participants with reoperation (for bleeding)
Time frame: Up to 30 days after surgery
Number of participants with reoperation (for reasons other than bleeding)
Time frame: Up to 30 days after surgery
Duration of mechanical ventilation
Time frame: Up to 30 days after surgery
Duration of intensive care unit (ICU) stay
Time frame: Up to 30 days after surgery
Duration of hospital stay
Time frame: Up to 30 days after surgery
21-day mortality
Time frame: Up to 21 days after surgery
In-hospital mortality
Time frame: Up to 30 days after surgery
Time between placing the investigational product (IP) order to administration
The following time to event parameters will be assessed: time between when IP is ordered and when IP is ready to administer in the operating room and time between when IP is ordered and start of IP administration.
Time frame: During surgery
Prothrombin time and activated partial thromboplastin time
Time frame: Up to 8 days after surgery
Coagulation parameter profile
The following coagulation parameter profiles will be assessed: thrombin generation marker, protein C and S, antithrombin and alpha 2-antiplasmin.
Time frame: Up to 8 days after surgery
Coagulation factor profile
The following coagulation factor profiles will be assessed: fibrinogen, factor VIII (FVIII):C, von Willebrand ristocetin cofactor (VWF:Rco) and factor XIII (FXIII).
Time frame: Up to 8 days after surgery
Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available
Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2027 → Jun 2027 and completion Oct 2027 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Homo sapiens whole